Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Arm Phase II Study Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in Patients With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Next Previous
Trial Profile

A Single Arm Phase II Study Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in Patients With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camptothecin (Primary) ; Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 17 Apr 2019 Planned End Date changed from 30 Jun 2020 to 30 Jun 2021.
    • 26 Mar 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 29 Mar 2019 to 1 Apr 2019.
    • 23 Mar 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Mar 2019 to 29 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top